Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer

Author:

Lee Catherine1ORCID,Jiang Ziyue Karen2ORCID,Planken Simon3ORCID,Manzuk Lisa K.4ORCID,Ortiz Roberto5ORCID,Hall Michael5ORCID,Noorbehesht Kavon2ORCID,Ram Sripad6ORCID,Affolter Timothy6ORCID,Troche Gabriel E.1ORCID,Ihle Nathan T.1ORCID,Johnson Theodore7ORCID,Ahn Youngwook8ORCID,Kraus Manfred1ORCID,Giddabasappa Anand2ORCID

Affiliation:

1. 1Oncology Research and Development, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.

2. 2Global Science & Technology – Comparative Medicine, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.

3. 3Oncology Medicinal Chemistry, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.

4. 4Comparative Medicine, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.

5. 5BioMedicine Design, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.

6. 6Drug Safety Research and Development Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.

7. 7Medicine Design, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.

8. 8Target Sciences, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.

Abstract

Abstract KRAS is one of the most commonly mutated oncogenes in lung, colorectal, and pancreatic cancers. Recent clinical trials directly targeting KRAS G12C presented encouraging results for a large population of non–small cell lung cancer (NSCLC), but resistance to treatment is a concern. Continued exploration of new inhibitors and preclinical models is needed to address resistance mechanisms and improve duration of patient responses. To further enable the development of KRAS G12C inhibitors, we present a preclinical framework involving translational, non-invasive imaging modalities (CT and PET) and histopathology in a conventional xenograft model and a novel KRAS G12C knock-in mouse model of NSCLC. We utilized an in-house developed KRAS G12C inhibitor (Compound A) as a tool to demonstrate the value of this framework in studying in vivo pharmacokinetic/pharmacodynamic (PK/PD) relationship and anti-tumor efficacy. We characterized the Kras G12C-driven genetically engineered mouse model (GEMM) and identify tumor growth and signaling differences compared to its Kras G12D-driven counterpart. We also find that Compound A has comparable efficacy to sotorasib in the Kras G12C-driven lung tumors arising in the GEMM, but like observations in the clinic, some tumors inevitably progress on treatment. These findings establish a foundation for evaluating future KRAS G12C inhibitors that is not limited to xenograft studies and can be applied in a translationally relevant mouse model that mirrors human disease progression and resistance.

Funder

Pfizer Inc

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3